12:00 AM
Feb 23, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Droxidopa: Additional Phase III data

A second analysis of data from the open-label titration portion of the placebo-controlled, international Phase III Study 302 trial showed that droxidopa produced a 4.2-unit mean improvement of dizziness or light-headedness on the OHSA scale. Responders also had a mean increase in standing SBP of 25 mmHg. Previously announced data showed that droxidopa produced a...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >